CDMO Signed, Oral Drug Locked, Phase 2 Moves From Plan To Execution

Quantum secured a leading CDMO to manufacture the oral formulation of Lucid MS for its upcoming Phase 2 trial. That removes a major CMC risk and shortens time from IND to first patient in. Oral dosing improves adherence and lowers site burden, which helps PET MRI biomarker quality. Stack this with the clean Phase 1 safety CSR and an IND now in preparation, and the path is visible: IND acceptance, site activation, interim imaging, topline data. On the tape, 25.40 holds as support, 26.00 is the near trigger, 28.00 next, with modeling still pointing at 35.26 on continued execution. This is operational proof, not talk.